Announcing a new publication for Acta Materia Medica journal. Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease. Verbascoside is a ubiquitous phenylethanoid glycoside with potent anti-inflammatory, antioxidant, and hypoglycemic properties. This paper determines the renoprotective effect of verbascoside against DKD, as well as the underlying mechanism. After administration of verbascoside for 4 consecutive weeks, the fasting blood glucose level, albumin:creatinine ratio, and podocyte damage in diabetic mice were alleviated, especially at a dose of 150 mg/kg/d. Moreover, the inflammatory response, cell apoptosis, and autophagy were improved in a dose-dependent fashion in the kidneys of diabetic mice and high glucose-stimulated podocytes. Verbascoside reversed the elevated NR4A1 expression and suppressed LKB1 to inhibit AMPKα phosphorylation. Silencing NR4A1 inhibited LKB1 and phospho-AMPKα expression, and relieved the stress response in injured podocytes. Taken together, the results indicate that verbascoside alleviates DKD-associated podocyte injury by regulating NR4A1-LKB1-AMPK signaling.
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to email@example.com.
Please visit https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
Xinyun Chen, Min Shi and Letian Yang et al. Phenylethanoid glycoside verbascoside ameliorates podocyte injury of diabetic kidney disease by regulating NR4A1-LKB1-AMPK signaling. Acta Materia Medica. Vol. 2(1):72-83. DOI: 10.15212/AMM-2022-0044